Previous Chapter Chapter 8: Contrasting European and US Patent Laws: Issues for the Pharmaceutical Industry Next Chapter

By: Decision Resources Inc

In: The SAGE Handbook of Healthcare

Chapter 8: Contrasting European and US Patent Laws: Issues for the Pharmaceutical Industry

  • Citations
  • Add to My List
  • Text Size

Contrasting European and US Patent Laws: Issues for the Pharmaceutical Industry
Contrasting european and US patent laws: Issues for the pharmaceutical industry
Overview

Patents have become the lifeblood of the biopharmaceutical industry, which depends heavily on intellectual property (IP) protection (especially patents and trade secrets) to justify and support its investment in R&D. Without IP protection, generic drug companies could develop products that match the physical and chemical specifications of innovator products and behave in a comparable manner and enter the market within only a few years of the introduction of a new drug product. Such a short period of exclusivity would not give developers of new molecular entities enough time to recoup their investments in R&D.

In addition to supporting laws protecting patents, most industrialized nations also ...

Looks like you do not have access to this content.

Login

Don’t know how to login?

Click here for free trial login.

Back to Top

Copy and paste the following HTML into your website